Characteristics of Teenagers Presenting with Chest Pain after COVID-19 mRNA Vaccination.

Publication date: Jun 30, 2023

In this study, we evaluated the clinical and radiological manifestations of teenagers presenting with chest pain after coronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccination. We retrospectively enrolled 61 teenage patients, aged 13 to 19 years, who underwent echocardiography and cardiac magnetic resonance imaging (CMR) for chest pain after COVID-19 mRNA vaccination, from November 2021 to April 2022. Medical records, laboratory results, echocardiographic, and CMR findings were analyzed. The mean age of the participants was 14. 4 +/- 1. 9 years, with a male:female ratio of 28:33. Among the sixty-one patients with chest pain after COVID-19 vaccination, only two (3. 3%) were diagnosed as confirmed myocarditis, and almost all of them recovered with conservative treatments. However, on CMR, 24 (39. 3%) presented with mild myocardial abnormalities; 22 (36. 1%) showed myocardial edema, and 19 (31. 1%) were found to have a myocardial injury. Multivariate logistic analyses revealed that older age and female sex were significantly associated with myocardial abnormalities. In teenagers who present with chest pain after COVID-19 mRNA vaccination, confirmed myocarditis is uncommon. However, myocardial abnormalities on CMR might occur frequently, and females in their late teens might be more vulnerable to myocardial abnormalities.

Open Access PDF

Concepts Keywords
April cardiac MRI
Coronavirus chest pain
Mild COVID-19
Myocarditis echocardiography
Radiological mRNA


Type Source Name
disease MESH Chest Pain
disease MESH COVID-19
disease VO vaccination
disease MESH myocarditis
disease MESH abnormalities
disease MESH edema
disease VO effective
disease VO vaccine
disease VO injection
disease IDO host
disease IDO symptom
disease MESH clinical significance
drug DRUGBANK Coenzyme M
disease IDO history
disease IDO blood
drug DRUGBANK Iron
disease VO IroN
disease VO protocol
disease VO USA
drug DRUGBANK Pentaerythritol tetranitrate
drug DRUGBANK Gadoteric acid
drug DRUGBANK Gadolinium
disease VO Canada
disease VO volume
disease MESH stroke
disease MESH Pericardial effusion
disease VO laboratory test
disease MESH asthma
pathway KEGG Asthma
disease MESH diabetes mellitus
disease MESH autoimmune diseases
drug DRUGBANK Hexachlorophene
drug DRUGBANK N-Cyclohexyltaurine
drug DRUGBANK Guanosine
drug DRUGBANK (S)-Des-Me-Ampa
disease IDO cell
disease MESH inflammation
drug DRUGBANK Sulfasalazine
drug DRUGBANK Acetohydroxamic acid
disease MESH heart failure
disease VO immunization

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *